StockMacro
Menu

Lexeo Therapeutics

$2.96 -42% in 6 monthsMarket cap $245.1M

LXEO on XNAS, Health Care, Lexeo Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Short interest reached 21% of shares as the stock fell 67% in a year.

  • BadNet loss $105.3M over 12 months, against $219.1M cash
  • GoodInstitutional holders rose to 152 from 142, up 7.0%

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
59
Website
lexeotx.com
Listed
Nasdaq, US
Last results
16 Nov 2026
Next results
expected around 29 Mar 2027 (an estimate: a year ago it reported on 30 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $38.3M.
Quarter to 31 Mar 2022: revenue –, net income -$12.5MQuarter to 30 Jun 2022: revenue –, net income -$15.1MQuarter to 30 Sep 2022: revenue $531K, net income -$17.1MQuarter to 30 Sep 2022: revenue $531K, net income -$17.1MQuarter to 31 Dec 2022: revenue $0, net income $104.0MQuarter to 31 Dec 2022: revenue $0, net income $104.0MQuarter to 31 Mar 2023: revenue –, net income -$18.7MQuarter to 30 Jun 2023: revenue –, net income -$13.4MQuarter to 30 Sep 2023: revenue –, net income -$20.1MQuarter to 31 Mar 2024: revenue –, net income -$21.7MQuarter to 30 Jun 2024: revenue –, net income -$21.2MQuarter to 30 Sep 2024: revenue –, net income -$29.5MQuarter to 31 Dec 2024: revenue –, net income -$25.9MQuarter to 31 Mar 2025: revenue –, net income -$32.7MQuarter to 30 Jun 2025: revenue –, net income -$26.1MQuarter to 30 Sep 2025: revenue –, net income -$20.3MQuarter to 31 Dec 2025: revenue –, net income -$20.9MQuarter to 31 Mar 2026: revenue –, net income -$20.2MQuarter to 30 Jun 2026: revenue –, net income -$25.9MQuarter to 30 Sep 2026: revenue –, net income -$38.3M
31 Mar 2022RevenueNet incomeNet losstallest bar $104.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$38.3M
30 Jun 2026–-$25.9M
31 Mar 2026–-$20.2M
31 Dec 2025–-$20.9M
30 Sep 2025–-$20.3M
30 Jun 2025–-$26.1M
31 Mar 2025–-$32.7M
31 Dec 2024–-$25.9M
30 Sep 2024–-$29.5M
30 Jun 2024–-$21.2M
31 Mar 2024–-$21.7M
30 Sep 2023–-$20.1M
30 Jun 2023–-$13.4M
31 Mar 2023–-$18.7M
31 Dec 2022$0$104.0M
30 Sep 2022$531K-$17.1M
30 Jun 2022–-$15.1M
31 Mar 2022–-$12.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$105.3M -$105.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.12 -$2.70
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -62.4% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $219.1M $122.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.62
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Lexeo TherapeuticsLXEO (this company) $245.1Mloss–––
Protalix BioTherapeuticsPLX $244.5M11.92.9+37%24.3%
Editas MedicineEDIT $253.1Mloss5.1+7.4%-145%
SAB BiotherapeuticsSABS $253.1Mloss–––
Eikon TherapeuticsEIKN $256.8M––––
OcugenOCGN $260.6Mloss54.5-11%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$18K

bought $0, sold $18K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+7.0%

152 13F filers vs 142

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

91.6M shares held by 13F filers (30 Sep 2026) of 82.8M outstanding (12 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

21%

17.0M shares sold short (30 Oct 2026) of 82.8M outstanding (12 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

12.7

17.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-2.9%

17.6M shares sold short in the report before, 17.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 56%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

10

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

40

40 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

10×

40 articles in the last 7 days; its usual week has 4.

Price $2.96 on 20 Nov 2026, -67% over 12 months (12-month range $2.63 to $10.63)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $739K in the last 12 months (the 12 months before: -$371K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $35K in the latest quarter.
Institutional holders (13F filers). 152 13F filers reported holding it in the latest 13F quarter, +42% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
29 Sep 20268-K and other filingsCompleted an acquisition or asset sale
2 Jun 2026Sharp changeShort interest spike: short interest spike, 13.2M vs usual 6.0M (2026-05-15); 4.2x the same period a year earlier
12 May 2026Sharp changeShort interest spike: short interest spike, 13.1M vs usual 5.9M (2026-04-30); 4.0x the same period a year earlier
30 Apr 20268-K and other filingsDirector or officer change
5 Feb 20268-K and other filingsDirector or officer change
27 Jan 20268-K and other filingsDirector or officer change
27 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Oct 2025Sharp changeShort interest spike: short interest spike, 7.3M vs usual 2.8M (2025-10-15); 3.6x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 6.0M vs usual 2.5M (2025-09-30); 2.9x the same period a year earlier
30 Sep 2025Sharp changeShort interest spike: short interest spike, 5.9M vs usual 2.5M (2025-09-15); 4.9x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 5.2M vs usual 2.4M (2025-08-29); 4.2x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 5.3M vs usual 2.3M (2025-08-15); 2.7x the same period a year earlier
14 Aug 20258-K and other filingsDirector or officer change
14 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Aug 2025Sharp changeShort interest spike: short interest spike, 5.2M vs usual 2.3M (2025-07-31); 3.2x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 5.2M vs usual 2.2M (2025-07-15); 6.2x the same period a year earlier
1 Jul 2025Sharp changeShort interest spike: short interest spike, 4.8M vs usual 2.2M (2025-06-13); 7.6x the same period a year earlier
19 Dec 20248-K and other filingsDirector or officer change
13 Nov 20248-K and other filingsDirector or officer change
13 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Jul 20248-K and other filingsDirector or officer change
22 Apr 20248-K and other filingsDirector or officer change
22 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Apr 20248-K and other filingsRegistered new securities for sale (S-1)
10 Nov 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 12.5M)
1 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
30 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
29 Sep 20238-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Nov 2023: $12.5M published
Month from 1 May 2024: -$66K published
Month from 1 Jun 2024: -$88K published
Month from 1 Jul 2024: -$923K published
Month from 1 Aug 2024: -$58K published
Month from 1 Sep 2024: -$53K published
Month from 1 Oct 2024: -$40K published
Month from 1 Nov 2024: $85K published
Month from 1 Dec 2024: -$20K published
Month from 1 Feb 2025: -$45K published
Month from 1 May 2025: -$7K published
Month from 1 Aug 2025: -$33K published
Month from 1 Oct 2025: -$233K published
Month from 1 Nov 2025: -$31K published
Month from 1 Feb 2026: -$84K published
Month from 1 Apr 2026: -$313K published
Month from 1 May 2026: -$24K published
Month from 1 Jul 2026: -$257K published
Month from 1 Aug 2026: -$43K published
Month from 1 Nov 2026: -$18K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 30 Sep 2022: $531K; public on 12 Dec 2023
Quarter ended 31 Dec 2022: $0; public on 12 Mar 2024
Capital spending per quarter
Quarter ended 31 Dec 2022: $25K; public on 12 Mar 2024
Quarter ended 30 Sep 2023: $3K; public on 12 Dec 2023
Quarter ended 31 Dec 2023: $73K, +192% on a year earlier; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $185K; public on 10 May 2024
Quarter ended 30 Jun 2024: $213K; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $83K, +2667% on a year earlier; public on 14 Nov 2024
Quarter ended 30 Sep 2025: $289K, +248% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $35K; public on 12 May 2026
Institutional holders (13F filers)
31 Dec 2023 report: 28; public on 14 Feb 2024
31 Mar 2024 report: 51; public on 15 May 2024
30 Jun 2024 report: 58; public on 14 Aug 2024
30 Sep 2024 report: 66; public on 14 Nov 2024
31 Dec 2024 report: 88; public on 14 Feb 2025
31 Mar 2025 report: 86; public on 15 May 2025
30 Jun 2025 report: 87; public on 14 Aug 2025
30 Sep 2025 report: 107; public on 14 Nov 2025
31 Dec 2025 report: 140; public on 17 Feb 2026
31 Mar 2026 report: 133; public on 15 May 2026
30 Jun 2026 report: 142; public on 14 Aug 2026
30 Sep 2026 report: 152; public on 16 Nov 2026
Federal obligations
Month from 1 Oct 2022: $0 published
Month from 1 Nov 2022: $0 published
Month from 1 Sep 2023: $0 published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $34.5M (30 Sep 2026), 2.1× its normal quarter; higher than 100% of its own history.
  • Short interest spike: had 13.2M shares sold short in the 15 May 2026 report, 4.2× the same report last year Public on 28 May 2026.
  • Insider net buying (open market): Insiders sold a net $739K in the last 12 months (the 12 months before: -$371K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 52 insider trades

Last 90 days: 3 sales, $18K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Louis Edward TamayoChief Financial OfficerSell1,007$3.26$3KForm 4
18 Nov 2026Jose Manuel OteroChief Operating OfficerSell1,285$3.26$4KForm 4
18 Nov 2026Richard Nolan TownsendChief Executive OfficerSell3,295$3.26$11KForm 4
19 Aug 2026Richard Nolan TownsendChief Executive OfficerSell3,345$4.95$17KForm 4
19 Aug 2026Jose Manuel OteroChief Operating OfficerSell1,304$4.96$6KForm 4
19 Aug 2026Louis Edward TamayoChief Financial OfficerSell4,117$4.91$20KForm 4
1 Jul 2026Jose Manuel OteroChief Operating OfficerSell4,666$4.48$21KForm 4
1 Jul 2026Narinder Pal BhallaChief Medical OfficerSell22,306$4.42$99KForm 4

152 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 28 opened a position, 17 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Affinity Asset Advisors, LLC7.2M8.75%$24.5M+1.4M+25%
Montanova Capital, LLC6.4M7.71%$21.6MNo change
BlackRock, Inc.6.0M7.22%$20.2M+234K+4.1%
Ra Capital Management, L.P.5.0M6.04%$16.9MNo change
Frazier Life Sciences Management, L.P.4.8M5.83%$16.3MNo change
JPMorgan Chase & Co4.6M5.54%$15.7M+4.5M48 times as many
Vestal Point Capital, LP4.3M5.22%$14.6MNo change
Citadel Advisors LLC4.2M5.12%$14.3M+338K+8.7%
Balyasny Asset Management L.P.4.0M4.82%$13.5M+1.6M+65%
Millennium Management LLC3.8M4.56%$12.8M+945K+33%

Company events

All 18 company events

In 12 months: 3 director or officer changes, 1 major agreement, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Sep 2026Completed an acquisition or asset saleSame filing: sold shares privately8-K
22 Sep 2026Signed a major agreement8-K
30 Apr 2026Director or officer change8-K
5 Feb 2026Director or officer change8-K
27 Jan 2026Director or officer change8-K
17 Oct 2025Signed a major agreementSame filing: sold shares privately8-K
14 Aug 2025Director or officer change8-K
27 May 2025Signed a major agreementSame filing: sold shares privately8-K

10 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 50%, Marketing & communications 20%, Finance & accounting 10%, Program & project management 10%.

PostedJobLocation
18 Nov 2026Manager/Senior Manager, Clinical Innovation and Corporate CommunicationsMarketing & communicationsNew York, New York
16 Nov 2026Associate Director, Capital Markets FinanceFinance & accountingNew York, New York
4 Nov 2026Associate Director, MarketingMarketing & communicationsNew York, New York
21 Oct 2026Scientist I/II, Modality EngineeringResearch & scienceNew York, New York
21 Oct 2026Scientist I/II, In Vivo PharmacologyResearch & scienceNew York, New York
13 Oct 2026Scientist II, Cellular Neuroscience and Translational PharmacologyResearch & scienceNew York, New York
15 Sep 2026Manager/Senior Manager, CMC Quality ControlTest, quality & reliabilityNew York, New York
15 Sep 2026Scientist II, Analytical DevelopmentResearch & scienceNew York, New York

The 5 newest of 193 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 29 Sep 2026Filings record

    Completed an acquisition or asset sale

  2. 28 May 2026Short interest and volume change

    had 13.2M shares sold short in the 15 May 2026 report, 4.2× the same report last year.

    Same report last year: 3.1M; its normal report is 6.0M.

    See the evidence
    This period
    13.2M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    6.0M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +3.8
    Same report last year
    3.1M
    History used
    912 days
    2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M2025-08-15: 5.3M2025-08-29: 5.2M2025-09-15: 5.9M2025-09-30: 6.0M2025-10-15: 7.3M2025-10-31: 5.2M2025-11-14: 5.6M2025-11-28: 6.0M2025-12-15: 7.1M2025-12-31: 10.8M2026-01-15: 11.5M2026-01-30: 12.0M2026-02-13: 11.5M2026-02-27: 11.1M2026-03-13: 11.8M2026-03-31: 12.5M2026-04-15: 12.6M2026-04-30: 13.1M2026-05-15: 13.2M
    the 15 May 2026 report24 earlier reportsnormal: 6.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 12 May 2026Short interest and volume change

    had 13.1M shares sold short in the 30 Apr 2026 report, 4.0× the same report last year.

    Same report last year: 3.3M; its normal report is 5.9M.

    See the evidence
    This period
    13.1M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    5.9M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +3.8
    Same report last year
    3.3M
    History used
    897 days
    2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M2025-08-15: 5.3M2025-08-29: 5.2M2025-09-15: 5.9M2025-09-30: 6.0M2025-10-15: 7.3M2025-10-31: 5.2M2025-11-14: 5.6M2025-11-28: 6.0M2025-12-15: 7.1M2025-12-31: 10.8M2026-01-15: 11.5M2026-01-30: 12.0M2026-02-13: 11.5M2026-02-27: 11.1M2026-03-13: 11.8M2026-03-31: 12.5M2026-04-15: 12.6M2026-04-30: 13.1M
    the 30 Apr 2026 report24 earlier reportsnormal: 5.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 30 Apr 2026Filings record

    Director or officer change

  5. 5 Feb 2026Filings record

    Director or officer change

  6. 27 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 27 Jan 2026Filings record

    Director or officer change

  8. 25 Oct 2025Short interest and volume change

    had 7.3M shares sold short in the 15 Oct 2025 report, 3.6× the same report last year.

    Same report last year: 2.1M; its normal report is 2.8M.

    See the evidence
    This period
    7.3M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    2.8M
    Typical spread (median absolute deviation)
    633K
    How far from its usual level
    +4.9
    Same report last year
    2.1M
    History used
    700 days
    2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M2025-08-15: 5.3M2025-08-29: 5.2M2025-09-15: 5.9M2025-09-30: 6.0M2025-10-15: 7.3M
    the 15 Oct 2025 report24 earlier reportsnormal: 2.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 10 Oct 2025Short interest and volume change

    had 6.0M shares sold short in the 30 Sep 2025 report, 2.9× the same report last year.

    Same report last year: 2.1M; its normal report is 2.5M.

    See the evidence
    This period
    6.0M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    2.5M
    Typical spread (median absolute deviation)
    482K
    How far from its usual level
    +4.8
    Same report last year
    2.1M
    History used
    685 days
    2024-09-30: 2.1M2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M2025-08-15: 5.3M2025-08-29: 5.2M2025-09-15: 5.9M2025-09-30: 6.0M
    the 30 Sep 2025 report24 earlier reportsnormal: 2.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 25 Sep 2025Short interest and volume change

    had 5.9M shares sold short in the 15 Sep 2025 report, 4.9× the same report last year.

    Same report last year: 1.2M; its normal report is 2.5M.

    See the evidence
    This period
    5.9M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    2.5M
    Typical spread (median absolute deviation)
    444K
    How far from its usual level
    +5.2
    Same report last year
    1.2M
    History used
    670 days
    2024-09-13: 1.2M2024-09-30: 2.1M2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M2025-08-15: 5.3M2025-08-29: 5.2M2025-09-15: 5.9M
    the 15 Sep 2025 report24 earlier reportsnormal: 2.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 11 Sep 2025Short interest and volume change

    had 5.2M shares sold short in the 29 Aug 2025 report, 4.2× the same report last year.

    Same report last year: 1.2M; its normal report is 2.4M.

    See the evidence
    This period
    5.2M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    2.4M
    Typical spread (median absolute deviation)
    409K
    How far from its usual level
    +4.7
    Same report last year
    1.2M
    History used
    653 days
    2024-08-30: 1.2M2024-09-13: 1.2M2024-09-30: 2.1M2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M2025-08-15: 5.3M2025-08-29: 5.2M
    the 29 Aug 2025 report24 earlier reportsnormal: 2.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 27 Aug 2025Short interest and volume change

    had 5.3M shares sold short in the 15 Aug 2025 report, 2.7× the same report last year.

    Same report last year: 1.9M; its normal report is 2.3M.

    See the evidence
    This period
    5.3M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    322K
    How far from its usual level
    +6.2
    Same report last year
    1.9M
    History used
    639 days
    2024-08-15: 1.9M2024-08-30: 1.2M2024-09-13: 1.2M2024-09-30: 2.1M2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M2025-08-15: 5.3M
    the 15 Aug 2025 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 14 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 14 Aug 2025Filings record

    Director or officer change

  15. 12 Aug 2025Short interest and volume change

    had 5.2M shares sold short in the 31 Jul 2025 report, 3.2× the same report last year.

    Same report last year: 1.7M; its normal report is 2.3M.

    See the evidence
    This period
    5.2M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    322K
    How far from its usual level
    +6.2
    Same report last year
    1.7M
    History used
    624 days
    2024-07-31: 1.7M2024-08-15: 1.9M2024-08-30: 1.2M2024-09-13: 1.2M2024-09-30: 2.1M2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M2025-07-31: 5.2M
    the 31 Jul 2025 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 25 Jul 2025Short interest and volume change

    had 5.2M shares sold short in the 15 Jul 2025 report, 6.2× the same report last year.

    Same report last year: 841K; its normal report is 2.2M.

    See the evidence
    This period
    5.2M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    319K
    How far from its usual level
    +6.2
    Same report last year
    841K
    History used
    608 days
    2024-07-15: 841K2024-07-31: 1.7M2024-08-15: 1.9M2024-08-30: 1.2M2024-09-13: 1.2M2024-09-30: 2.1M2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M2025-06-30: 5.2M2025-07-15: 5.2M
    the 15 Jul 2025 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 26 Jun 2025Short interest and volume change

    had 4.8M shares sold short in the 13 Jun 2025 report, 7.6× the same report last year.

    Same report last year: 629K; its normal report is 2.2M.

    See the evidence
    This period
    4.8M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    308K
    How far from its usual level
    +5.7
    Same report last year
    629K
    History used
    576 days
    2024-06-14: 629K2024-06-28: 776K2024-07-15: 841K2024-07-31: 1.7M2024-08-15: 1.9M2024-08-30: 1.2M2024-09-13: 1.2M2024-09-30: 2.1M2024-10-15: 2.1M2024-10-31: 2.2M2024-11-15: 2.5M2024-11-29: 2.2M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 2.3M2025-01-31: 1.9M2025-02-14: 2.3M2025-02-28: 2.4M2025-03-14: 2.2M2025-03-31: 2.6M2025-04-15: 2.9M2025-04-30: 3.3M2025-05-15: 3.1M2025-05-30: 3.8M2025-06-13: 4.8M
    the 13 Jun 2025 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 19 Dec 2024Filings record

    Director or officer change

  19. 27 Nov 2024Insiders record

    CHOLMONDELEY PAULA H (director) bought 15,000 shares of LXEO ($104,850) (dated 26 Nov 2024)

  20. 13 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 13 Nov 2024Filings record

    Director or officer change

  22. 8 Jul 2024Filings record

    Director or officer change

  23. 22 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 22 Apr 2024Filings record

    Director or officer change

  25. 9 Apr 2024Filings record

    Registered new securities for sale (S-1)

  26. 10 Nov 2023Insiders change

    had 3 insiders buy $12.5M of its shares on the open market within 30 days (3 filings).

    Who bought: Lundbeckfond Invest A/S.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $12.5M
    Window
    11 Oct 2023 to 10 Nov 2023

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  27. 10 Nov 2023Insiders record

    Paster Anne-Mari (ten percent owner) and 5 other(s) bought 454,545 shares of LXEO ($5.0M) (dated 9 Nov 2023)

  28. 10 Nov 2023Insiders record

    Lundbeckfond Invest A/S (ten percent owner) bought 227,272 shares of LXEO ($2.5M) (dated 9 Nov 2023)

  29. 10 Nov 2023Insiders record

    Longitude Venture Partners IV, L.P. (ten percent owner) and 3 other(s) bought 454,545 shares of LXEO ($5.0M) (dated 9 Nov 2023)

  30. 1 Nov 2023Filings record

    Registered new securities for sale (S-1)

  31. 30 Oct 2023Filings record

    Registered new securities for sale (S-1)

  32. 29 Sep 2023Filings record

    Registered new securities for sale (S-1)

Not listed: 97 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001907108
Ticker
LXEO
Domain
lexeotx.com
Employer name
Lexeo Therapeutics, Inc. (1 unverified)
Hq location
NY|NEW YORK|10010 (1 unverified)
Name
Lexeo Therapeutics, Inc.
Uei
GV7VALHZMNR7
  • DOL H-1B labor condition applications and PERM certifications25 data points30 Aug 2021 to 2 Feb 2026
  • SEC Form 13F institutional holdings108 data points31 Dec 2023 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)62 records29 Sep 2023 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)214 data points31 Dec 2021 to 12 Nov 2026
  • SEC Form 4 insider transactions52 records, 84 data points9 Nov 2023 to 18 Nov 2026
  • FINRA short interest (twice monthly)215 data points15 Nov 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1530 data points3 Nov 2023 to 20 Nov 2026
  • USASpending.gov federal awards42 data points2 Feb 2018 to 9 Aug 2023